Treatment of Hypertension in Children With Catecholamine-Secreting Tumors: A Systematic Approach

J Clin Hypertens (Greenwich). 2015 Sep;17(9):720-5. doi: 10.1111/jch.12571. Epub 2015 May 23.

Abstract

Management of blood pressure in children with pheochromocytoma and other catecholamine-secreting tumors (CSTs) is unique and challenging. The authors report a single-center experience using sequential α-adrenergic blockade (phenoxybenzamine), increased fluid intake, and β-blockade for presurgical management of 10 CSTs in children. In this retrospective review, mean duration for blood pressure control in preparation for surgery was 4.5±2.6 weeks. Intraoperative hypertension was noted transiently (<2 hours) in eight patients (80%) and was treated with continuous infusion of short-acting antihypertensive agents. Two (20%) patients required vasopressor medication infusion to manage intraoperative hypotension. Only two (20%) patients developed postoperative hypotension and required vasopressor medication infusion for <24 hours. All antihypertensive medications were discontinued in the immediate (≤4 days) postoperative period in 80% of patients. In conclusion, a systematic and multidisciplinary approach utilizing adrenergic blockade is effective in treating children with CSTs.

MeSH terms

  • Adolescent
  • Adrenal Gland Neoplasms / surgery
  • Adrenergic alpha-Antagonists / therapeutic use*
  • Antihypertensive Agents / therapeutic use*
  • Blood Pressure / drug effects
  • Blood Pressure / physiology*
  • Catecholamines / blood
  • Catecholamines / metabolism*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Hypertension / complications*
  • Hypertension / drug therapy*
  • Hypotension / complications
  • Hypotension / drug therapy*
  • Infant
  • Intraoperative Period
  • Male
  • Phenoxybenzamine / therapeutic use*
  • Pheochromocytoma / complications*
  • Pheochromocytoma / metabolism
  • Pheochromocytoma / pathology
  • Pheochromocytoma / surgery*
  • Postoperative Period
  • Retrospective Studies
  • Treatment Outcome
  • Von Hippel-Lindau Tumor Suppressor Protein / metabolism

Substances

  • Adrenergic alpha-Antagonists
  • Antihypertensive Agents
  • Catecholamines
  • Phenoxybenzamine
  • Von Hippel-Lindau Tumor Suppressor Protein
  • VHL protein, human